Ribomic (4591), listed on the Tokyo Stock Exchange's Growth market, announced a revision to its earnings forecast at 3:30 p.m. on Oct. 20, 2026.
The filing, titled "Notice Regarding Revision of Earnings Forecast" (業績予想の修正に関するお知らせ), was released through the exchange's TDnet disclosure system.
The previous and revised forecast figures, the size of the revision and the reasons given are set out in the company's full filing and are not reproduced here.
| Item | Detail |
|---|---|
| Company | Ribomic |
| Ticker | 4591 |
| Market | TSE Growth |
| Released | Oct. 20, 2026, 3:30 p.m. JST |
| Filing type | Earnings forecast revision |
| Hikari Tsushin, Inc. | |
| Offer price | ¥1,000 per common share |
| M&A / TOB | 1 |
| Guidance | 0 |
| Buybacks | 0 |
| Dividends | 0 |
| Capital | 0 |
| Earnings | 0 |
| People | 0 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理,非投資建議,亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。